Cyp asx

Morningstar Investor users sign in here. Skip to Content. Market Centre.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance. Media centre.

Cyp asx

Cynata Therapeutics Limited. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. About the company. CYP Stock Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Revenue is forecast to grow Volatile share price over the past 3 months. Shareholders have been diluted in the past year. Currently unprofitable and not forecast to become profitable over the next 3 years. Has less than 1 year of cash runway. New minor risk - Financial position Feb New major risk - Financial position Aug See more updates Recent updates.

Trade our cash market.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech.

Key events shows relevant news articles on days with large price movements. Mesoblast Ltd. MSB 7. Starpharma Holdings Ltd. SPL 3. Anteris Technologies Ltd. AVR 0. Regeneus Ltd.

Cyp asx

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US.

Pak vs hong kong asia cup 2018

Cynata Therapeutics Limited Fundamentals Summary. Subscribe to our newsletters. Getting started. Advertise with Us. Show more Tech link Tech. Start investing. Cancel Continue. Participants resources. Upcoming Dividends. Search the FT Search. Roundup of Global market movements.

Cynata Therapeutics Limited.

Global Market Report. Actions Add to watchlist Add to portfolio Add an alert. Our research. Upcoming Dividends. Fixed Income. ASX Compliance. Last Reported Earnings Dec 31, Price Volatility. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. CYP Stock Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cancel Continue. Trade our derivatives market.